IDO1 and pancreatic neoplasm: Use of a dual inhibitor IDO1/TDO (RY103) effectively suppressed IDO1 in a pre-clinical murine pancreatic cancer model [193] and might be a new avenue to be considered in circumventing the inhibitory action of IDO1 in NK cell-mediated cytotoxicity.